Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydroxyethyl starch (HES) and albumin are two distinct colloid solutions used for plasma volume expansion in clinical settings. They are often compared or used as alternatives to each other, rather than being a single combination product. Hydroxyethyl starch is a synthetic colloid used for preventing shock following severe blood loss caused by trauma, surgery, or other issues. It's available in various formulations, with 6% HES 130/0.4 being a common version. HES may reduce capillary leakage and maintains blood volume for at least 6 hours after administration[3][8]. Albumin (typically 5% concentration) is a natural plasma protein that serves as an alternative colloid for volume replacement. It interacts with the endothelial glycocalyx, which appears to provide protective effects on the vascular barrier[1]. Both solutions are used in perioperative fluid management, hypovolemia treatment, and other clinical scenarios requiring plasma volume expansion[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydroxyethyl starch + albumin.